bladder cancer aggressiveness

Little is known about the metabolic adaptations that alter the tumour microenvironment and thus contribute to chemoresistance in urothelial bladder cancer (UBC). Here we describe that CD147 and MCT1 overexpression associates with UBC aggressiveness. Moreover, platinum-treated patients with MCT1 and CD147 positive tumours have worse prognosis. CD147 depletion reduces MCTs expression and improves cisplatin response in UBC cells. Our results provide novel insights for the involvement of CD147 and MCTs in UBC progression and chemoresistance.